Business Description
ConvaTec Group PLC
ISIN : GB00BD3VFW73
Description
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.85 | |||||
| Debt-to-EBITDA | 2.87 | |||||
| Interest Coverage | 3.74 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.48 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.5 | |||||
| 3-Year EBITDA Growth Rate | 4.4 | |||||
| 3-Year EPS without NRI Growth Rate | 6 | |||||
| 3-Year FCF Growth Rate | -7.4 | |||||
| 3-Year Book Growth Rate | 1.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.57 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.66 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.3 | |||||
| 9-Day RSI | 51.65 | |||||
| 14-Day RSI | 52.77 | |||||
| 6-1 Month Momentum % | -12.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | |||||
| Quick Ratio | 1.27 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 148.69 | |||||
| Days Sales Outstanding | 56.37 | |||||
| Days Payable | 100.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.05 | |||||
| Dividend Payout Ratio | 0.46 | |||||
| 3-Year Dividend Growth Rate | 6.8 | |||||
| Forward Dividend Yield % | 2.05 | |||||
| 5-Year Yield-on-Cost % | 2.17 | |||||
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | 2.79 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.96 | |||||
| Operating Margin % | 13.23 | |||||
| Net Margin % | 6.96 | |||||
| FCF Margin % | 11.64 | |||||
| ROE % | 9.23 | |||||
| ROA % | 4.14 | |||||
| ROIC % | 6.9 | |||||
| ROC (Joel Greenblatt) % | 32.1 | |||||
| ROCE % | 8.49 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 42.9 | |||||
| Forward PE Ratio | 17.97 | |||||
| PE Ratio without NRI | 23.7 | |||||
| Shiller PE Ratio | 222.34 | |||||
| Price-to-Owner-Earnings | 22.41 | |||||
| PEG Ratio | 29.63 | |||||
| PS Ratio | 2.95 | |||||
| PB Ratio | 3.91 | |||||
| Price-to-Free-Cash-Flow | 25.13 | |||||
| Price-to-Operating-Cash-Flow | 17.16 | |||||
| EV-to-EBIT | 27.25 | |||||
| EV-to-Forward-EBIT | 20.51 | |||||
| EV-to-EBITDA | 15.15 | |||||
| EV-to-Forward-EBITDA | 11.7 | |||||
| EV-to-Revenue | 3.37 | |||||
| EV-to-Forward-Revenue | 3.15 | |||||
| EV-to-FCF | 30.15 | |||||
| Price-to-Projected-FCF | 1.69 | |||||
| Earnings Yield (Greenblatt) % | 3.66 | |||||
| FCF Yield % | 4.21 | |||||
| Forward Rate of Return (Yacktman) % | 4.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ConvaTec Group PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,031.036 | ||
| EPS (TTM) (€) | 0.068 | ||
| Beta | 1.08 | ||
| Volatility % | 26.56 | ||
| 14-Day RSI | 52.77 | ||
| 14-Day ATR (€) | 0.063424 | ||
| 20-Day SMA (€) | 2.797 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 2.52 - 3.44 | ||
| Shares Outstanding (Mil) | 2,045.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ConvaTec Group PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ConvaTec Group PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ConvaTec Group PLC Frequently Asked Questions
What is ConvaTec Group PLC(FRA:2CV)'s stock price today?
The current price of FRA:2CV is €2.84. The 52 week high of FRA:2CV is €3.44 and 52 week low is €2.52.
When is next earnings date of ConvaTec Group PLC(FRA:2CV)?
The next earnings date of ConvaTec Group PLC(FRA:2CV) is 2025-03-06 Est..
Does ConvaTec Group PLC(FRA:2CV) pay dividends? If so, how much?
The Dividend Yield %  of ConvaTec Group PLC(FRA:2CV) is 2.05% (As of Today), Highest Dividend Payout Ratio of ConvaTec Group PLC(FRA:2CV) was 0.49. The lowest was 0.08. And the median was 0.46. The  Forward Dividend Yield % of ConvaTec Group PLC(FRA:2CV) is 2.05%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers